Meta-analysis of 43 studies of neoadjuvant/adjuvant immune checkpoint inhibitors: fatigue was more frequent than with placebo (RR 1.21, 95% CI 1.08-1.35), with slightly higher patient-reported fatigue; no significant difference versus chemotherapy. Risk of bias was high.
Meta-analysisn = 43 studies
Potter et al. Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis